Performance of the disease risk score in a cohort study with policy-induced selection bias-Reference-Cited by-同舟云学术

Performance of the disease risk score in a cohort study with policy-induced selection bias

Published:2015-11 Issue:6 Volume:4 Page:607-614
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Tadrous Mina¹²³,Mamdani Muhammad M¹²³⁴,Juurlink David N²⁵,Krahn Murray D¹²⁴⁶,Lévesque Linda E²⁷,Cadarette Suzanne M¹²

Affiliation:

1. Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON, M5S 3M2, Canada

2. Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, M4N 3M5, Canada

3. Applied Health Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada

4. Institute of Health Policy, Management & Evaluation, University of Toronto, 27 King's College Cir, Toronto, ON, M5S, Canada

5. Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON, M4N 3M5T, Canada

6. Toronto Health Economics & Technology Assessment (THETA) Collaborative, Toronto, ON, M5S 3M2, Canada

7. Department of Public Health Sciences, Queen's University, 99 University Ave., Kingston, ON K7L 3N6, Canada

Abstract

Aim: To examine the performance of the disease risk score (DRS) in a cohort study with evidence of policy-induced selection bias. Methods: We examined two cohorts of new users of bisphosphonates. Estimates for 1-year hip fracture rates between agents using DRS, exposure propensity scores and traditional multivariable analysis were compared. Results: The results for the cohort with no evidence of policy-induced selection bias showed little variation across analyses (-4.1–2.0%). Analysis of the cohort with evidence of policy-induced selection bias showed greater variation (-13.5–8.1%), with the greatest difference seen with DRS analyses. Conclusion: Our findings suggest that caution may be warranted when using DRS methods in cohort studies with policy-induced selection bias, further research is needed.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer.15.40

Reference43 articles.

1. Methodologic Challenges to Studying Patient Safety and Comparative Effectiveness

2. Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research

3. Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development

4. Changing patterns of use of osteoporosis medications in the years after launch: implications for comparative effectiveness research